Home  >  News
you can get e-magazine links on WhatsApp.Click here
biopol
Corporate + Font Resize -

Glenmark’s subsidiary gets US FDA approval for Ryaltris nasal spray to treat seasonal allergic rhinitis

Our Bureau, Mumbai
Friday, January 14, 2022, 12:30 Hrs  [IST]

Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, announced that its fully owned subsidiary Glenmark Specialty S.A. (Switzerland), received US FDA approval on its New Drug Application (NDA) for Ryaltris, an innovative, fixed dose (metered), prescription, combination drug product nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and paediatric patients 12 years of age and older in the United States.
\
“The FDA’s approval of Ryaltris represents a major milestone for Glenmark and clearly supports our efforts to bring innovative treatment options in our key therapeutic areas.” said Robert Crockart, chief commercial officer of Glenmark Pharmaceuticals Limited. “With this NDA approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms.”
 
Ryaltris will be marketed and distributed in the United States (US) by Hikma Specialty USA, Inc., as part of its exclusive licensing agreement with Glenmark Specialty SA (Switzerland).
 
Ryaltris is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray approved by the FDA for the treatment of symptoms associated with seasonal allergic rhinitis. Each unit of Ryaltris nasal spray contains 665 mcg of olopatadine hydrochloride, a histamine-1(H1)-receptor inhibitor, and 25 mcg of mometasone furoate, a corticosteroid. The combination drug product nasal spray is indicated for the treatment of symptoms associated with seasonal allergic rhinitis in adults and paediatric patients 12 years of age and older. The safety and effectiveness of Ryaltris in paediatric patients younger than 12 years of age has not been established.
 
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily.
 
Ryaltris will be marketed and distributed in the United States through our partner Hikma Specialty USA Inc., Columbus, OH.
 
Ryaltris has been approved and is marketed in Australia, the Czech Republic, Poland, Russia, South Africa, Ukraine, the United Kingdom, and Uzbekistan. In April 2021, Glenmark concluded the DCP regulatory procedure in Europe, enabling approval in 17 countries across EU and UK.
 
Glenmark has entered into commercial agreements with several partners around the world, including Menarini for the commercialization of Ryaltris in select EU markets, and with Bausch Health in Canada where it is under review by Health Canada).

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |